U.S. Federal

U.S. Federal

Beyond Reefer Madness: The U.S. Fed's role in cannabis policy.

cannabis with ladybug
The EPA has refused to offer guidance for pesticides on cannabis.
Stethascope and money
The magnified focus on economic incentives and tax revenue has overshadowed the significance of cannabis as medicine.
pills and dollars
Doctors at the Mayo Clinic recently highlighted a case of price gouging on vitamin K1.
An overview of the evolving regulatory status of CBD.
How will botanical CBD be regulated when cannabidiol is approved as a pharmaceutical?
Doctor writing
The Society of Cannabis Clinicians calls for more sensible policies towards cannabis, including research collaboration with doctors and medical cannabis dispensaries.
DEA, CBD, Schedule 1
In December of 2016, the DEA announced that it is implementing new rules that may portend a crackdown on CBD oil products. Educate yourself.
Photograph of a kratom leaf on a yellow background.
Why are the FDA and DEA trying to block people's access to kratom by making it a Schedule 1 drug?
Huge interest in the medicinal potential of CBD has catalyzed a rebirth of industrial hemp in the U.S. But is hemp the best source of CBD?
Jahan Marcu discusses lab testing, safety protocols, adverse events reporting, and regulatory standards for the cannabis industry.

Thanks to our sponsors and supporters:

Top Stories